Evaluating the impact of an AI cancer prediction platform on early interception of the five deadliest cancers: A retrospective study using real-world data.

560 Background: Early diagnosis remains a critical challenge in oncology, particularly for the five deadliest cancers: lung, breast, prostate, colorectal, and pancreatic. These cancers often present with nonspecific symptoms, leading to repeated healthcare visits without a timely suspicion of malignancy. Artificial intelligence (AI) offers an opportunity to augment clinical decision-making and support earlier identification of cancer. C the Signs , an AI cancer prediction platform, has been widely adopted across the UK with substantial evidence supporting its ability to identify cancer at earlier stages. Methods: This retrospective study assessed the performance of C the Signs in intercepting cancer earlier than physician diagnosis. De-identified electronic medical records were accessed via the Mayo Data Platform, spanning a 20-year period from January 1, 2002 to December 31, 2021. The study cohort included 55,375 patients diagnosed with lung, breast, prostate, colorectal or pancreatic cancer. The primary outcome was the proportion of cases identified earlier by the AI model, measured in annual increments up to five years prior to physician diagnosis. Additional analyses were conducted across the five target cancer types. Results: The C the Signs platform identified 14,528 patients (26.2%) with lung cancer earlier than the original physician diagnosis. Early identification occurred across multiple time points: 8.9% in year 1, 4.7% in year 2, 4.4% in year 3, 4.3% in year 4, and 3.9% in year 5. Across cancer types, the highest early interception rate was observed in prostate cancer (31.7%), while breast cancer showed the lowest impact (21.0%). Conclusions: Use of the C the Signs AI cancer prediction platform demonstrated meaningful improvements in early cancer interception, particularly for lung and prostate cancers. These findings highlight the potential of AI tools to enhance early diagnosis and support timely clinical interventions, offering a scalable solution to improve cancer outcomes across populations.